The mission of the ALODF is to increase living donation, not ensure living donor safety. Sigrid Fry Revere, the group's founder and primary member, has written numerous articles (and one book) defending Iran's kidney market, and just co-authored a paper (published march 2015) that endorses the "testing" of incentives in the U.S. (Despite the fact that every analysis from every country - including Iran - concludes that markets are highly detrimental the person selling their kidney).
Kidney transplants are not cures, but treatments. Because there are other treatments for kidney failure, namely dialysis, a transplant DOES NOT "save a life".
Meanwhile, this article glosses over the risks of donation to the donor, as well as the systemic deficits living donors endure.
4.4 living kidney donors die every year in the US within 12 months of surgery (per OPTN and SRTR data).
20% experience complications: hernia, pancreatitis, intestinal blockage, adrenal dysfunction, nerve damage, testicular swelling/sensitivity, etc.
30% suffer from depression, anxiety, grief, anger and/or PTSD. Transplant centers are not required to, nor do they, offer structured aftercare or support services.
The US had no national standards of care until 2013. The current standards are so vague that if a potential LKD is rejected, the transplant center *must* tell the potential LKD that s/he can be evaluated and accepted at another hospital with "different selection criteria".
60 years after the first living kidney donor transplant and we still have NO COMPREHENSIVE LIVING DONOR DATA.